The effectiveness clears the way for pricing, which typically occurs within 1-2 business days. Monitor for a subsequent prospectus (424B4) disclosing the exact terms. The lack of a concurrent underwritten deal announcement suggests the company may be using an at-the-market (ATM) facility or a best-efforts structure, which could prolong the dilution overhang.
Price Chart
Executive Summary
The SEC declared effective FibroBiologics' registration statement on Form S-1 (File No. 333-280303) on October 19, 2026, enabling the company to proceed with a securities offering. As a clinical-stage biopharmaceutical company, this effectiveness opens the door for potential capital raising, which introduces dilution risk for existing shareholders.
Key Facts
- Effectiveness date: October 19, 2026
- Registration statement File No.: 333-280303
- Form type: S-1 (IPO/primary offering) — the filing references a POS AM (post-effective amendment) to the S-1
- Company: FibroBiologics, Inc. (FBLG), a clinical-stage pharmaceutical preparer
- No offering size, price, or terms disclosed in the EFFECT notice
Financial Impact
Undisclosed — the EFFECT notice does not specify the offering size, share count, or price range. Typical clinical-stage biotech offerings range from $10M to $100M.
Risk Factors
- Imminent share dilution from the now-effective offering
- Clinical-stage company with no approved products — capital needs are high and cash runway is likely limited
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003282 |
| Document: 9999999995-26-003282-index.html | 9999999995-26-003282 |
| Document: 9999999995-26-003282.txt | 9999999995-26-003282 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 20, 2026 6d ago | EFFECT | $0.9199 | awaiting T+5 | — | $0.9221 (−0.24%) |
Oct 8, 2026 17d ago | 8-K | $1.13 $0.9710 | ▲ +14.07% | ▲ +12.10% | $0.9221 (+18.40%) |
Sep 15, 2026 5w ago | 8-K | $1.44 $1.43 | ▼ −0.69% | ▼ −1.51% | $0.9221 (−35.97%) |
Aug 24, 2026 9w ago | 8-K | $1.35 $1.72 | ▲ +27.41% | ▲ +26.94% | $0.9221 (−31.70%) |
Jul 31, 2026 12w ago | Press Release | $0.7910 $0.9800 | ▲ +23.89% | ▲ +21.87% | $0.9221 (+16.57%) |
Jul 17, 2026 14w ago | EFFECT | $0.8349 $0.7355 | ▲ +11.91% | ▲ +11.22% | $0.9221 (−10.44%) |
Jul 9, 2026 15w ago | 8-K | $0.8610 $0.8398 | ▼ −2.46% | ▼ −2.33% | $0.9221 (+7.10%) |
Jun 29, 2026 16w ago | 8-K | $0.9477 $0.8687 | ▲ +8.34% | ▲ +8.94% | $0.9221 (+2.70%) |
May 11, 2026 24w ago | Press Release | $0.9900 $1.09 | ▲ +10.10% | ▲ +10.19% | $0.9221 (−6.86%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers